Itamar Medical Reports Success in Clinical Study Validating WatchPAT®️ for Central Sleep Apnea Differentiation, Submits Application for FDA Clearance of New WatchPAT®️ Version

New version of WatchPAT distinguishes between different subtypes of Sleep Apnea, ensuring a suitable therapeutic solution for patients

CAESAREA, Israel, June 9, 2016 – Itamar Medical Ltd. (TASE.ITMR), which develops, manufactures, and markets non-invasive diagnostic medical devices for cardiology and sleep related breathing disorders, reported success in a comprehensive clinical study based on initial results reported this week, and an FDA submission for a new WatchPAT version.

Site by Imaginet
Site by Imaginet